XML 13 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Balance Sheets - USD ($)
Jun. 30, 2018
Sep. 30, 2017
CURRENT ASSETS    
Cash and cash equivalents $ 27,995,386 $ 24,838,567
Accounts receivable 14,975 67,797
Prepaid expenses 1,095,977 867,363
Other current assets 279,049 1,359,638
Short term investments 32,484,708 40,769,539
TOTAL CURRENT ASSETS 61,870,095 67,902,904
Long term investments 17,672,658  
Property and equipment, net 14,029,239 15,513,019
Intangible assets, net 19,189,117 20,464,439
Other assets 141,918 141,918
TOTAL ASSETS 112,903,027 104,022,280
CURRENT LIABILITIES    
Accounts payable 2,165,731 4,076,514
Accrued expenses 2,163,533 4,564,507
Accrued payroll and benefits 1,147,780 3,399,679
Deferred rent 440,580 440,580
Deferred revenue 943,200 5,269,741
Derivative liabilities   695,114
Note Payable 219,889 208,506
Other current liabilities 46,407 46,407
TOTAL CURRENT LIABILITIES 7,127,120 18,701,048
LONG-TERM LIABILITIES    
Deferred rent, net of current portion 1,657,899 1,929,052
Note Payable, net of current portion 2,158,649 2,325,018
Other non-current liabilities 200,000 200,000
TOTAL LONG-TERM LIABILITIES 4,016,548 4,454,070
Commitments and contingencies (Note 7)
Arrowhead Pharmaceuticals, Inc. stockholders' equity:    
Common stock, $0.001 par value; 145,000,000 shares authorized; 87,854,651 and 74,785,426 shares issued and outstanding as of June 30, 2018 and September 30, 2017, respectively 180,224 167,155
Additional paid-in capital 578,642,206 514,037,301
Accumulated other comprehensive income (loss) (3,338) 33,232
Accumulated deficit (476,504,545) (432,815,338)
Total Arrowhead Pharmaceuticals, Inc. stockholders' equity 102,314,547 81,422,350
Noncontrolling interest (555,188) (555,188)
TOTAL STOCKHOLDERS’ EQUITY 101,759,359 80,867,162
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 112,903,027 $ 104,022,280